Tessa Reports First Patient Dosing in P-Ib Clinical Trial of TT11 as 2L Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma
Shots:
- The first patient has been dosed in the P-Ib trial to evaluate TT11 + BMS’ nivolumab in ~14 patients with r/r CD30+ cHL. Patients will receive 2 cycles of nivolumab given at intervals of 4wks., followed by CT that depletes lymphocytes using fludarabine/bendamustine
- The 1EPs of the trial are safety & tolerability of the combination regimen & 2EPs incl. ORR, DoR & PFS. The results from the pilot part of the P-II (CHARIOT) trial for TT11 showed a favorable safety profile and promising efficacy in patients with r/r cHL, CR rate of 57.1% & ORR of 71.4%
- The company plans to advance the therapy in (CHARIOT) trial in 2022 & improved an allogeneic "off-the-shelf" cell therapy platform that targets a variety of cancers and augments EBVSTs with CD30-CAR
Ref: Globe Newswire | Image: Tessa
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
